Recent approaches in chemoprevention of prostate cancer

Current Cancer Drug Targets

Volumn 7, Issue 7, 2007, Pages 681-688

  Young, Charles Y F ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chemoprevention; Dietary chemicals; Epigenetic; Genetic polymorphism; Prostate cancer

Indexed keywords

3,3' DIINDOLYLMETHANE; ALPHA TOCOPHEROL; ANDROGEN RECEPTOR; ANTIANDROGEN; ASCORBIC ACID; CALCITRIOL; CALCIUM; CARBOPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DNA METHYLTRANSFERASE INHIBITOR; DUTASTERIDE; FINASTERIDE; FOLIC ACID; GENISTEIN; HISTONE DEACETYLASE INHIBITOR; INDOLE DERIVATIVE; LYCOPENE; QUERCETIN; RALOXIFENE; RESVERATROL; RETINOL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELENIUM; TAMOXIFEN; TAXANE DERIVATIVE; TOREMIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; ZINC;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER PREVENTION; CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVITY; EPIGENETICS; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; PROSTATE CANCER; REVIEW; TARGET CELL; UNITED STATES;

ANIMALS; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 35948993029     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907782418284     Document Type: Review

References (165)

1. Bostwick, D. G.; Burke, H. B.; Djakiew, D.; Euling, S.; Ho, S. M.; Landolph, J.; Morrison, H.; Sonawane, B.; Shifflett, T.; Waters, D. J.; Timms, B. Human prostate cancer risk factors. Cancer 2004, 101(Suppl. 10), 2371-2490.
2. Brand, T. C.; Canby-Hagino, E. D.; Pratap Kumar, A.; Ghosh, R.; Leach, R. J.; Thompson, I. M. Chemoprevention of prostate cancer. Hematol. Oncol. Clin. North Am. 2006, 20, 831-843.
3. Khan, N.; Afaq, F.; Saleem, M.; Ahmad, N.; Mukhtar, H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res. 2006, 66, 2500-2505.
4. Klein, E. A. Chemoprevention of prostate cancer. Annu. Rev. Med. 2006, 57, 49-63.
5. Lippman, S. M.; Lee, J. J. Reducing the "risk" of chemoprevention: defining and targeting high risk-2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res. 2006, 66, 2893-2903.
6. Lowe, J. F.; Frazee, L. A. Update on prostate cancer chemoprevention. Pharmacotherapy 2006, 26, 353-359.
7. Mahal, K.; Hernandez, J.; Basler, J. W.; Thompson, I. M. Curr. Med. Chem. Anticancer Agents 2005, 5, 603-612.
8. Nelson, W. G. Agents in development for prostate cancer prevention. Exp. Opin. Investig. Drugs 2004, 13, 1541-1554.
9. Shukla, S.; Gupta, S. Dietary agents in the chemoprevention of prostate cancer. Nutr. Cancer 2005, 53, 18-32.
10. Stewart, A. B.; Lwaleed, B. A.; Douglas, D. A.; Birch, B. R. Current drug therapy for prostate cancer: an overview. What's new in the field of prostate cancer chemoprevention? Curr. Urol. Rep. 2005, 6, 177-182.
11. Lambert, J. D.; Hong, J.; Yang, G. Y.; Liao, J.; Yang, C. S. Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am. J. Clin. Nutr. 2005, 81(Suppl. 1), 284S-291S.
12. Ganry, O. Phytoestrogens and prostate cancer risk. Prev. Med. 2005, 41, 1-6.
13. Kanadaswami, C.; Lee, L. T.; Lee, P. P.; Hwang, J. J.; Ke, F. C.; Huang, Y. T.; Lee, M. T. The antitumor activities of flavonoids. In Vivo 2005, 19, 895-909.
14. Scalbert, A.; Manach, C.; Morand, C.; Remesy, C.; Jimenez, L. Dietary polyphenols and the prevention of diseases. Crit. Rev. Food Sci. Nutr. 2005, 45, 287-306.
15. Chan, J. M.; Gann, P. H.; Giovannucci, E. L. Role of diet in prostate cancer development and progression. J. Clin. Oncol. 2005, 23, 8152-8160.
16. Schaid, D. J. The complex genetic epidemiology of prostate cancer. Human Mol. Genet. 2004, 13(Special Issue 1), R103-R121.
17. Aggarwal, B. B.; Shishodia, S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 2006, 71, 1397-1421.
18. Yoo, C. B.; Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 2006, 5, 37-50.
19. Dehm, S. M.; Tindall, D. J. Regulation of androgen receptor signaling in prostate cancer. Exp. Rev. Anticancer Ther. 2005, 5, 163-174.
20. Schulman, C. Use of 5-alpha-reductase inhibitors in the prevention of prostate cancer. Ann. Urol. 2004, 38(Suppl. 2), S35-S42.
21. E. D.; Brand, T. C.; Hernandez, J.; Thompson, I. M. Chemoprevention of prostate cancer with finasteride. Exp. Opin. Pharmacother. 2006, 7, 899-905.
22. Andriole, G.; Bostwick, D.; Civantos, F.; Epstein, J.; Lucia, M. S.; McConnell, J.; Roehrborn, C. G. The effects of 5 alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: Current state of knowledge. J. Urol. 2005, 174, 2098-2104.
23. Teillac, P.; Abrahamsson, P. A. The Prostate Cancer Prevention Trial and its implications for clinical practice: A European consensus. Eur. Urol. Suppl. 2006, 5, 640-646.
24. Lowe, J. F.; Frazee, L. A. Update on prostate cancer chemoprevention. Pharmacotherapy 2006, 26, 353-359.
25. Andriole, G.; Bostwick, D.; Brawley, O.; Gomella, L.; Tindall, D.; Breed, S.; Somerville, M.; Rittmaster, R. Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial. J. Urol. 2004, 172, 1314-1317.
26. Gomella, L. G. Chemoprevention using dutasteride: the REDUCE trial. Curr. Opin. Urol. 2005, 15, 29-32.
27. Zhao, X. H.; Li, L. L.; Wang, Z. Y. Chemoprevention of breast cancer: current status and future prospects. Front. Biosci. 2006, 11, 2249-2256.
28. O'Regan, R. M. Chemoprevention of breast cancer. Lancet 2006, 367, 1382-1383.
29. Kazmin, D.; Prytkova, T.; Cook, C. E.; Wolfinger, R.; Chu, T. M.; Beratan, D.; Norris, J. D.; Chang, C. Y.; McDonnell, D. P. Linking ligand-induced alterations in androgen receptor structure to differential gene expression: A first step in the rational design of selective androgen receptor modulators. Mol. Endocrin. 2006, 20, 1201-1217.
30. Baek, S. H.; Ohgi, K. A.; Nelson, C. A.; Welsbie, D.; Chen, C.; Sawyers, C. L.; Rose, D. W.; Rosenfeld, M. G. Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proc. Natl. Acad. Sci. USA 2006, 103, 3100-3105.
31. Bohl, C. E.; Miller, D. D.; Chen, J. Y.; Bell, C. E.; Dalton, J. T. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J. Biol. Chem. 2005, 280, 37747-37754.
32. Le, H. T.; Schaldach, C. M.; Firestone, G. L.; Bjeldanes, L. F. Plant-derived 3,3 '-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J. Biol. Chem. 2003 , 278, 21136-21145.
33. Young, C. Y. F.; Jatoi, A.; Ward, J. F.; Blute, M. L. The effects of dietary factors on the androgen receptor and related cellular factors in prostate cancer. Cur. Med. Chem. 2004, 11, 909-923.
34. Yuan, H.; Pan, Y.; Young, C. Y. Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett. 2004, 213, 155-163.
35. Yuan, H. Q.; Gong, A. Y.; Young, C. Y. F. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis 2005, 26, 793-801.
36. Leav, I.; Ho, S.; Ofner, P.; Merk, F.; Kwan, P.; Damassa, D. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J. Natl. Cancer Inst. 1988 , 80, 1045-1053.
37. Pollard, M. Prevention of prostate-related cancers in Lobund-Wistar rats. Prostate 1999 , 39, 305-309.
38. King, K. J.; Nicholson, H. D.; Assinder, S. J. Effect of increasing ratio of estrogen: Androgen on proliferation of normal human prostate stromal and epithelial cells, and the malignant cell line LNCaP. Prostate 2006, 66, 105-114.
39. Kirschenbaum, A.; Liu, X. H.; Yao, S.; Narla, G.; Friedman, S. L.; Martignetti, J. A.; Levine, A. C. Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones. Carcinogenesis 2006, 27, 216-224.
40. Ho, S. M. Estrogens and anti-estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates. J. Cell Biochem. 2004, 91, 491-503.
41. Bonkhoff, H.; Fixemer, T. Implications of estrogens and their receptors for the development and progression of prostate cancer. Pathologe 2005, 26, 461-468.
42. Ho, S. M.; Tang, W. Y.; de Frausto, J. B.; Prins, G. S. Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res. 2006, 66, 5624-5632.
43. Hernandez, J.; Balic, I.; Johnson-Pais, T. L.; Higgins, B. A.; Torkko, K. C.; Thompson, I. M.; Leach, R. J. Association between an eestrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. J. Urol. 2006, 175, 523-527.
44. Thellenberg-Karlsson, C.; Lindstrom, S.; Malmer, B.; Wiklund, F.; Augustsson-Balter, K.; Adami, H. O.; Stattin, P.; Nilsson, M.; Dahlman-Wright, K.; Gustafsson, J. A.; Gronberg, H. Estrogen receptor beta polymorphism is associated with prostate cancer risk. Clin. Cancer Res. 2006, 12, 1936-1941.
45. Taneja, S. S.; Smith, M. R.; Dalton, J. T.; Raghow, S.; Barnette, G. Toremifene - a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Exp. Opin. Investig. Drugs 2006, 15, 293-305.
46. Steiner, M. S.; Raghow, S. Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk. World J. Urol. 2006, 21, 31-36.
47. Usui, T. Pharmaceutical prospects of phytoestrogens. Endocr. J. 2006, 53, 7-20.
48. Sirtori, C. R.; Arnoldi, A.; Johnson, S. K. Phytoestrogens: End of a tale? Ann. Med. 2005, 37, 423-438.
49. Ma, Z. S.; Huynh, T. H.; Ng, C. P.; Do, P. T.; Nguyen, T. H.; Huynh, H. Reduction of CWR22 prostate tumor xenograft growth by combined tamoxifen-quercetin treatment is associated with inhibition of angiogenesis and cellular proliferation. Int. J. Oncol. 2004, 24, 1297-1304.
50. Stein, S.; Zoltick, B.; Peacock, T.; Holroyde, C.; Haller, D.; Armstead, B.; Malkowicz, S. B.; Vaughn, D. J. Phase II trial of toremifene in androgen-independent prostate cancer - A Penn cancer clinical trials group trial. Amer. J. Clin. Oncol. Cancer Clin. Trials 2001, 24, 283-285.
51. Raghow, S.; Hooshdaran, M. Z.; Katiyar, S.; Steiner, M. S. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res. 2002, 62, 1370-1376.
52. Shazer, R. L.; Jain, A.; Galkin, A. V.; Cinman, N.; Nguyen, K. N.; Natale, R. B.; Gross, M.; Green, L.; Bender, L. I.; Holden, S.; Kaplan, L.; Agus, D. B. Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU Int. 2006, 97, 691-697.
53. Kim, I. Y.; Kim, B. C.; Seong, D. H.; Lee, D. K.; Seo, J. M.; Hong, Y. J.; Kim, H. T.; Morton, R. A.; Kim, S. J. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res. 2002, 62, 5365-5369.
54. Smith, M. R.; Fallon, M. A.; Lee, H.; Finkelstein, J. S. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized controlled trial. J. Clin. Endocr. Metab. 2004, 89, 3841-384.
55. Gross, M. D. Vitamin D and calcium in the prevention of prostate and colon cancer: new approaches for the identification of needs. J. Nutr. 2005, 135, 326-331.
56. Severi, G.; English, D. R.; Hopper, J. L.; Giles, G. G. Re: Prospective studies of dairy product and calcium intakes and prostate cancer risk: A meta-analysis. J. Nat. Cancer Inst. 2006, 98, 794-795.
57. Kesse, E.; Bertrais, S.; Astorg, P.; Jaouen, A.; Arnault, N.; Galan, P.; Hercberg, S. Dairy products, calcium and phosphorus intake, and the risk of prostate cancer: results of the French prospective SU.VI.MAX (Supplementation en Vitamines et Mineraux Antioxydants) study. Br. J. Nutr. 2006, 95, 539-545.
58. Dagnelie, P. C.; Schuurman, A. G.; Goldbohm, R. A.; Van den Brandt, P. A. Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int. 2004, 93, 1139-1150.
59. Giovannucci, E.; Liu, Y.; Stampfer, M. J.; Willett, W. C. Prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 203-210.
60. Costello, L. C.; Franklin, R. B.; Feng, P.; Tan, M.; Bagasra, O. Zinc and prostate cancer: a critical scientific, medical, and public interest issue (United States). Cancer Causes Control. 2005, 16, 901-915.
61. Zaichick, V. Y.; Sviridova, T. V.; Zaichick, S. V. Zinc in the human prostate gland: normal, hyperplastic and cancerous. Int. Urol. Nephrol. 1997 , 29, 565-574.
62. Jarrard, D. F. Does zinc supplementation increase the risk of prostate cancer? Arch. Ophthalmol. 2005, 123, 102-103.
63. Henshall, S. M.; Afar, D. E.; Rasiah, K. K.; Horvath, L. G.; Gish, K.; Caras, I.; Ramakrishnan, V.; Wong, M.; Jeffry, U.; Kench, J. G.; Quinn, D. I.; Turner, J. J.; Delprado, W.; Lee, C. S.; Golovsky, D.; Brenner, P. C.; O'Neill, G. F.; Kooner, R.; Stricker, P. D.; Gergiev, J. J.; Mack, D. H.; Sutherland, R. L. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene 2003 , 22, 6005-6012.
64. Rishi, I.; Baidouri, H.; Abbasi, J. A.; Bullard-Dillard, R.; Kajdacsy-Balla, A.; Pestaner, J. P.; Skacel, M.; Tubbs, R.; Bagasra, O. Prostate cancer in African American men is associated with downregulation of zinc transporters. Appl. Immunohistochem. Mol. Morphol. 2003 , 11, 253-260.
65. Liang, J. Y.; Liu, Y. Y.; Zou, J.; Franklin, R. B.; Costello, L. C.; Feng, P. Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate 1999 , 40, 200-220.
66. Uzzo, R. G.; Leavis, P.; Hatch, W.; Gabai, V. L.; Dulin, N.; Zvartau, N.; Kolenko, V. M. Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. Clin. Cancer Res. 2002, 8, 3579-358.
67. Whelan, P.; Walker, B. E.; Kelleher, J. Zinc, vitamin A and prostatic cancer. Br. J. Urol. 1983 , 55, 525-528.
68. Ogunlewe, J. O.; Osegbe, D. N. Zinc and cadmium concentrations in indigenous blacks with normal, hypertrophic, and malignant prostate. Cancer 1989 , 63, 1388-1392.
69. Feustel, A.; Wennrich, R.; Schmidt, B. Serum-Zn-levels in prostatic cancer. Urol. Res. 1989 , 17, 41-42.
70. Kristal, A. R.; Stanford, J. L.; Cohen, J. H.; Wicklund, K.; Patterson, R. E. Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 1999 , 8, 887-892.
71. Key, T. J.; Silcocks, P. B.; Davey, G. K.; Appleby, P. N.; Bishop, D. T. A case-control study of diet and prostate cancer. Br. J. Cancer 1997 , 76, 678-687.
72. Meyer, F.; Galan, P.; Douville, P.; Bairati, I.; Kegle, P.; Bertrais, S.; Estaquio, C.; Hercberg, S. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int. J. Cancer 2005, 116, 182-186.
73. Platz, E. A.; Helzlsouer, K. J.; Hoffman, S. C.; Morris, J. S.; Baskett, C. K.; Comstock, G. W. Prediagnostic toenail cadmium and zinc and subsequent prostate cancer risk. Prostate 2002, 52, 288-296.
74. Leitzmann, M. F.; Stampfer, M. J.; Wu, K. N.; Colditz, G. A.; Willett, W. C.; Giovannucci, E. L. Zinc supplement use and risk of prostate cancer. J. Nat. Cancer Inst. 2003 , 95, 1004-1007.
75. Barceloux, D. G. Selenium. J. Toxicol. - Clin. Toxicol. 1999 , 37, 145-172.
76. Clark, L. C.; Combs, G. F. Jr.; Turnbull, B. W.; Slate, E. H.; Chalker, D. K.; Chow, J.; Davis, L. S.; Glover, R. A.; Graham, G. F.; Gross, E. G.; Krongrad, A.; Lesher, J. L. Jr.; Park, H. K.; Sanders, B. B. Jr.; Smith, C. L.; Taylor, J. R. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 1996 , 276, 1957-1963.
77. Giovannucci, E. Selenium and risk of prostate cancer. Lancet 1998 , 352, 755-756.
78. Platz, E. A.; Helzlsouer, K. J. Selenium, zinc, and prostate cancer. Epidemiol. Rev. 2001, 23, 93-101.
79. El-Bayoumy, K. The protective role of selenium on genetic damage and on cancer. Mutat. Res. 2001, 475(1-2 Special Issue SI), 123-139.
80. Zu, K.; Ip, C. Synergy between selenium and vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells. Cancer Res. 2003 , 63, 6988-6995.
81. Wang, Z. S.; Jiang, C.; Lu, J. X. Induction of caspase-mediated apoptosis and cell-cycle G(1) arrest by selenium metabolite methylseleno. Mol. Carcinog. 2002, 34, 113-120.
82. Jiang, C.; Ganther, H.; Lu, J. X. Monomethyl selenium-specific inhibition of MMP-2 and VEGF expression: Implications for angiogenic switch regulation. Mol. Carcinog. 2000, 29, 236-250.
83. Jiang, C.; Wang, Z. S.; Ganther, H.; Lu, J. X. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol. Cancer Ther. 2002, 1, 1059-106.
84. Sinha, R.; Unni, E.; Ganther, H. E.; Medina, D. Methylseleninic acid, a potent growth inhibitor of synchronized mouse mammary epithelial tumor cells in vitro. Biochemical Pharmacol. 2001, 61, 311-317.
85. Swede, H.; Dong, Y.; Reid, M.; Marshall, J.; Ip, C. Cell cycle arrest biomarkers in human lung cancer cells after treatment with selenium in culture. Cancer Epidemiol. Biomarkers Prev. 2003 , 12, 1248-1252.
86. Cho, S. D.; Jiang, C.; Malewicz, B.; Dong, Y.; Young, C. Y. F.; Kang, K. S.; Lee, Y. S.; Ip, C. Lu, J. X. Methyl selenium metabolites decrease prostatespecific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Mol. Cancer Ther. 2004, 3, 605-611.
87. Dong, Y.; Lee, S. O.; Zhang, H.; Marshall, J.; Gao, A. C.; Ip, C. Prostatespecific antigen expression is down-regulated by selenium through disruption of antigen receptor signaling. Cancer Res. 2004, 64, 19-22.
88. Lipsky, K.; Zigeuner, R.; Zischka, M.; Schips, L.; Pummer, K.; Rehak, P.; Hubmer, G. Selenium levels of patients with newly diagnosed prostate cancer compared with control group. Urology 2004, 63, 912-916.
89. Allen, N. E.; Morris, J. S.; Ngwenyama, R. A.; Key, T. J. A case-control study of selenium in nails and prostate cancer risk in British men. Br. J. Cancer 2004, 90, 1392-1396.
90. Nyman, D. W.; Stratton, M. S.; Kopplin, M. J.; Dalkin, B. L.; Nagle, R. B.; Gandolfi, A. J. Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect. Prev. 2004, 28, 8-16.
91. Lippman, S. M.; Goodman, P. J.; Klein, E. A.; Parnes, H. L.; Thompson, I. M. Jr.; Kristal, A. R.; Santella, R. M.; Probstfield, J. L.; Moinpour, C. M.; Albanes, D.; Taylor, P. R.; Minasian, L. M.; Hoque, A.; Thomas, S. M.; Crowley, J. J.; Gaziano, J. M.; Stanford, J. L.; Cook, E. D.; Fleshner, N. E.; Lieber, M. M.; Walther, P. J.; Khuri, F. R.; Karp, D. D.; Schwartz, G. G.; Ford, L. G.; Coltman, C. A., Jr. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J. Natl. Cancer Inst. 2005, 97, 94-102.
92. Stevens, V. L.; McCullough, M. L.; Diver, W. R.; Rodriguez, C.; Jacobs, E. J.; Thun, M. J.; Calle, E. E. Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control. 2005, 16, 643-650.
93. Coulter, I. D.; Hardy, M. L.; Morton, S. C.; Hilton, L. G.; Tu, W. L.; Valentine, D.; Shekelle, P. G. Antioxidants vitamin C and vitamin E for the prevention and treatment of cancer. J. Gen. Intern. Med. 2006, 21, 735-744.
94. Kirsh, V. A.; Hayes, R. B.; Mayne, S. T.; Chatterjee, N.; Subar, A. F.; Dixon, L. B.; Albanes, D.; Andriole, G. L.; Urban, D. A.; Peters, U. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J. Nat. Cancer. Inst. 2006, 98, 245-254.
95. Chan, J. M.; Stampfer, M. J.; Ma, J.; Rimm, E. B.; Willett, W. C.; Giovannucci, E. L. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol. Biomarkers Prev. 1999 , 8, 893-899.
96. Rodriguez, C.; Jacobs, E. J.; Mondul, A. M.; Calle, E. E.; McCullough, M. L.; Thun, M. J. Vitamin E supplements and risk of prostate cancer in US men. Cancer Epidemiol. Biomarkers Prev. 2004, 13, 378-382.
97. Chang, S.; Erdman, J. W., Jr.; Clinton, S. K.; Vadiveloo, M.; Strom, S. S.; Yamamura, Y.; Duphorne, C. M.; Spitz, M. R.; Amos, C. I.; Contois, J. H.; Gu, X.; Babaian, R. J.; Scardino, P. T.; Hursting, S. D. Relationship between plasma carotenoids and prostate cancer. Nutr. Cancer 2005, 53, 127-134.
98. Kristal, A. R.; Stanford, J. L.; Cohen, J. H.; Wicklund, K.; Patterson, R. E. Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 1999 , 8, 887-892.
99. Jiang, Q.; Wong, J.; Fyrst, H.; Saba, J. D.; Ames, B. N. Gamma-tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis. Proc. Natl. Acad. Sci. USA 2004, 10, 17825-17830.
100. Srivastava, J. K.; Gupta, S. Tocotrienol-rich fraction of palm oil induces cell cycle arrest and apoptosis selectively in human prostate cancer cells. Biochem. Biophys. Res. Commun. 2006, 346, 447-453.
101. Key, T. J.; Appleby, P. N.; Allen, N. E.; Travis, R. C.; Roddam, A. W.; Jenab, M.; Egevad, L.; Tjonneland, A.; Johnsen, N. F.; Overvad, K.; Linseisen, J.; Rohrmann, S.; Boeing, H.; Pischon, T.; Psaltopoulou, T.; Trichopoulou, A.; Trichopoulos, D.; Palli, D.; Vineis, P.; Tumino, R.; Berrino, F.; Kiemeney, L.; Bueno-de-Mesquita, H. B.; Quiros, J. R.; Gonzalez, C. A.; Martinez, C.; Larranaga, N.; Chirlaque, M. D.; Ardanaz, E.; Stattin, P.; Hallmans, G.; Khaw, K. T.; Bingham, S.; Slimani, N.; Ferrari, P.; Rinaldi, S.; Riboli, E. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am. J. Clin. Nutr. 2007 , 86, 672-681.
102. Stahl, W.; Sies, H. Bioactivity and protective effects of natural carotenoids. Biochimi. Biophys. Acta 2005, 1740, 101-107.
103. Pasquali, D.; Rossi, V.; Bellastella, G.; Bellastella, A.; Sinisi, A. A. Natural and synthetic retinoids in prostate cancer. Curr. Pharm. Des. 2006, 12, 1923-1929.
104. Blomhoff, R.; Blomhoff, H. K. Overview of retinoid metabolism and function. J. Neurobiol. 2006, 66, 606-630.
105. Bertram, J. S.; Vine, A. L. Cancer prevention by retinoids and carotenoids: independent action on a common target. Biochim. Biophys. Acta 2005, 1740, 170-178.
106. Sharoni, Y.; Danilenko, M.; Dubi, N.; Ben-Dor, A.; Levy, J. Carotenoids and transcription. Arch. Biochem. Biophys. 2004, 430, 89-96.
107. Li, H. J.; Kantoff, P. W.; Giovannucci, E.; Leitzmann, M. F.; Gaziano, J. N.; Stampfer, M. J.; Ma, J. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res. 2005, 65, 2498-2504.
108. Perry, A. S.; Foley, R.; Woodson, K.; Lawler, M. The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr. Relat. Cancer 2006, 13, 357-377.
109. Hanson, J. A.; Gillespie, J. W.; Grover, A.; Tangrea, M. A.; Chuaqui, R. F.; Emmert-Buck, M. R.; Tangrea, J. A.; Libutti, S. K.; Linehan, W. M.; Woodson, K. G. Gene promoter methylation in prostate tumor-associated stromal cells. J. Natl. Cancer Inst. 2006, 98, 255-261.
110. Fang, M. Z.; Wang, Y.; Ai, N.; Hou, Z.; Sun, Y.; Lu, H.; Welsh, W.; Yang, C. S. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003 , 63, 7563-7570.
111. Fang, M. Z.; Chen, D.; Sun, Y.; Jin, Z.; Christman, J. K.; Yang, C. S. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin. Cancer Res. 2005, 11, 7033-7041.
112. Campbell, J. K.; Canene-Adams K.; Lindshield, B. L.; Boileau, T. W. M.; Clinton, S. K.; Erdman, J. W. Tomato phytochemicals and prostate cancer risk. J. Nutr. 2004, 134(12 Suppl. S), 3486S-3492S.
113. Pastori, M.; Pfander, H.; Boscoboinik, D.; Azzi, A. Lycopene in association with alpha-tocopherol inhibits at physiological concentrations proliferation of prostate carcinoma cells. Biochem. Biophys. Res. Commun. 1998 , 250, 582-585.
114. Limpens, J.; Schroder, F. H.; de Ridder, C. M.; Bolder, C. A.; Wildhagen, M. F.; Obermuller-Jevic, U. C.; Kramer, K.; van Weerden, W. M. Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice. J. Nutr. 2006, 136, 1287-1293.
115. Giovannucci, E.; Rimm, E. B.; Liu, Y.; Stampfer, M. J.; Willett, W. C. A, prospective study of tomato products, lycopene, and prostate cancer risk. J. Nat. Cancer Inst. 2002, 94, 391-398.
116. Giovannucci, E. A review of epidemiologic studies of tomatoes, lycopene, and prostate cancer. Exp. Biol. Med. 2002, 227, 852-859.
117. Jian, L.; Du, C. J.; Lee, A. H.; Binns, C. W. Do dietary lycopene and other carotenoids protect against prostate cancer? Int. J. Cancer 2005, 113, 1010-1014.
118. Kirsh, V. A.; Mayne, S. T.; Peters, U.; Chatterjee, N.; Leitzmann, M. F.; Dixon, L. B.; Urban, D. A.; Crawford, E. D.; Hayes, R. B. A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 92-98.
119. Schwartz, G. G.; Hanchette, C. L. UV, latitude, and spatial trends in prostate cancer mortality: All sunlight is not the same (United States). Cancer Causes Control. 2006, 17, 1091-1101.
120. Giovannucci, E.; Liu, Y.; Rimm, E. B.; Hollis, B. W.; Fuchs, C. S.; Stampfer, M. J.; Willett, W. C. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J. Natl. Cancer Inst. 2006, 98, 451-459.
121. Schwartz, G. G. Vitamin D and the epidemiology of prostate cancer. Semin. Dial. 2005, 18, 276-289.
122. Beer, T. M.; Myrthue, A. Calcitriol in the treatment of prostate cancer. Anticancer Res. 2006, 26, 2647-2651.
123. Trump, D. L.; Muindi, J.; Fakih, M.; Yu, W. D.; Johnson, C. S. Vitamin D compounds: clinical development as cancer therapy and prevention agents. Anticancer Res. 2006, 26, 2551-2556.
124. Flaig, T. W.; Barqawi, A.; Miller, G.; Kane, M.; Zeng, C.; Crawford, E. D.; Glode, L. M. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer 2006, 107, 266-274.
125. Abedin, S. A.; Banwell, C. M.; Colston, K. W.; Carlberg, C.; Campbell, M. J. Epigenetic corruption of VDR signalling in malignancy. Anticancer Res. 2006, 26, 2557-256.
126. Das, P. M.; Singal, R.; DNA methylation and cancer. J. Clin. Oncol. 2004, 22, 4632-4642.
127. Friso, S.; Choi, S. W. Gene-nutrient interactions in one-carbon metabolism. Curr. Drug Metab. 2005, 6, 37-46.
128. Rossi, E.; Hung, J.; Beilby, J. P.; Knuiman, M. W.; Divitini, M. L.; Bartholomew, H. Folate levels and cancer morbidity and mortality: Prospective cohort study from Busselton, Western Australia. Ann. Epidemiol. 2006, 16, 206-212.
129. Pelucchi, C.; Galeone, C.; Talamini, R.; Negri, E.; Parpinel, M.; Franceschi, S.; Montella, M.; La Vecchia, C. Dietary folate and risk of prostate cancer in Italy. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 944-948.
130. Hultdin, J.; Van Guelpen, B.; Bergh, A.; Hallmans, G.; Stattin, M. Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: A prospective study. Intl. J. Cancer 2005, 113, 819-824.
131. Stevens, V. L.; Rodriguez, C.; Pavluck, A. L.; McCullough, M. L.; Thun, M. J.; Calle, E. E. Folate nutrition and prostate cancer incidence in a large cohort of US men. Am. J. Epidemiol. 2006, 163, 989-996.
132. Cicek, M. S.; Nock, N. L.; Li, L.; Conti, D. V.; Casey, G.; Witte, J. S. Relationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressiveness. Cancer Epidemiol. Biomarkers Prev. 2004, 13, 1331-1336.
133. Singal, R.; Ferdinand, L.; Das, P. M.; Reis, I. M.; Schlesselman, J. J. Polymorphisms in the methylenetetrahydro-folate reductase gene and prostate cancer risk. Intl. J. Oncol. 2004, 25, 1465-1471.
134. Aggarwal, B. B.; Shishodia, S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 2006, 71, 1397-1421.
135. El-Bayoumy, K.; Sinha, R.; Pinto, J. T.; Rivlin, R. S. Cancer chemoprevention by garlic and garlic-containing sulfur and selenium compounds. J. Nutr. 2006, 136(3 Suppl. S), 864S-869S.
136. Martin, K. R. Targeting apoptosis with dietary biloactive agents. Exp. Biol. Med. 2006, 231, 117-129.
137. Moon, Y. J.; Wang, X. D.; Morris, M. E. Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism. Toxicol. in Vitro 2006, 20, 187-210.
138. Myzak, M. C.; Dashwood, R. H. Chemoprotection by sulforaphane: Keep one eye beyond Keap1. Cancer Lett. 2006, 233, 208-218.
139. Pinto, J. T.; Rivlin, R. S. Antiproliferative effects of allium derivatives from garlic. J. Nutr. 2001, 131, 1058S-1060S.
140. Shukla, S.; Gupta, S. Dietary agents in the chemoprevention of prostate cancer. Nutr. Cancer 2005, 53, 18-32.
141. Siddiqui, I. A.; Adhami, V. M.; Saleern, M.; Mukhtar, H. Beneficial effects of tea and its polyphenols against prostate cancer. Mol. Nutr. Food Res. 2006, 50, 130-143.
142. Yang, C. S.; Sang, S. M.; Lambert, J. D.; Hou, Z.; Ju, J. Y.; Lu, G. Possible mechanisms of the cancer-preventive activities of green tea. Mol. Nutr. Food Res. 2006, 50, 170-175.
143. Wu, X. J.; Kassie, F.; Mersch-Sundermann, V. Induction of apoptosis in tumor cells by naturally occurring sulfur-containing compounds. Mutat. Res. 2005, 589, 81-102.
144. Neuhouser, M. L. Dietary flavonoids and cancer risk: Evidence from human population studies. Nutr. Cancer 2004, 50, 1-7.
145. Kristal, A. R.; Lampe, J. W. Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. Nutr. Cancer 2002, 42, 1-9.
146. Joseph, M. A.; Moysich, K. B.; Freudenheim, J. L.; Shields, P. G.; Bowman, E. D.; Zhang, Y.; Marshall, J. R.; Ambrosone, C. B. Cruciferous vegetables, genetic polymorphisms in glutathione S-transferases M1 and T1, and prostate cancer risk. Nutr. Cancer 2004, 50, 206-221.
147. HemaIswarya, S.; Doble, M. Potential synergism of natural products in the treatment of cancer. Phytother. Res. 2006, 20, 239-249.
148. Graf, B. A.; Milbury, P. E, Blumberg, J. B. Flavonols, flavones, flavanones, and human health: epidemiological evidence. J. Med. Food 2005, 8, 281-290.
149. Dekker, M.; Verkerk, R. Dealing with variability in food production chains: a tool to enhance the sensitivity of epidemiological studies on phytochemicals. Eur. J. Nutr. 2003 , 42, 67-72.
150. Herman, J. G. Epigenetic changes in cancer and preneoplasia. Cold Spring Harb. Symp. Quant. Biol. 2005, 70, 329-333.
151. Li, L. C.; Carroll, P. R.; Dahiya, R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J. Natl. Cancer Inst. 2005, 97, 103-115.
152. Hassig, C. A.; Tong, J. K.; Schreiber, S. L. Fiber-derived butyrate and the prevention of colon cancer. Chem. Biol. 1997 , 4, 783-789.
153. Dashwood, R. H.; Myzak, M. C.; Ho, E. Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis 2006, 27, 344-349.
154. Myzak, M. C.; Karplus, P. A.; Chung, F. L.; Dashwood, R. H. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res. 2004, 64, 5767-5774.
155. Myzak, M. C.; Hardin, K.; Wang, R.; Dashwood, R. H.; Ho, E. Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis 2006, 27, 811-819.
156. Kang, J.; Chen, J.; Shi, Y.; Jia, J.; Zhang, Y. Curcumin-induced histone hypoacetylation: the role of reactive oxygen species. Biochem. Pharmacol. 2005, 69, 1205-1213.
157. Momparler, R. L. Epigenetic therapy of cancer with 5-aza-2′- deoxycytidine (decitabine). Semin. Oncol. 2005, 32, 443-451.
158. Uthus, E. O.; Ross, S. A.; Davis, C. D. Differential effects of dietary selenium (se) and folate on methyl metabolism in liver and colon of rats. Biol. Trace Elem. Res. 2006, 109, 201-214.
159. Kraunz, K. S.; Hsiung, D.; McClean, M. D.; Liu, M.; Osanyingbemi, J.; Nelson, H. H.; Kelsey, K. T. Dietary folate is associated with p16(INK4A) methylation in head and neck squamous cell carcinoma. Int. J. Cancer 2006, 119, 1553-1557.
160. Davis, C. D.; Uthus, E. O.; Finley, J. W. Dietary selenium and arsenic affect DNA methylation in vitro in Caco-2 cells and in vivo in rat liver and colon. J. Nutr. 2000, 131, 2903-2909.
161. Lee, W. J.; Zhu, B. T. Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis 2006, 27, 269-277.
162. Lee, W. J.; Shim, J. Y.; Zhu, B. T. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol. Pharmacol. 2005, 68, 1018-1030.
163. Ma, L.; Feugang, J. M.; Konarski, P.; Wang, J.; Lu, J.; Fu, S.; Ma, B.; Tian, B.; Zou, C.; Wang, Z. Growth inhibitory effects of quercetin on bladder cancer cell. Front. Biosci. 2006, 11, 2275-2285.
164. Klotz, L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr. Treat. Options Oncol. 2006, 7, 355-362.
165. Amling, C. L. Prostate-specific Antigen and Detection of Prostate Cancer: What Have We Learned and What Should We Recommend for Screening? Curr. Treat. Options Oncol. 2006, 7, 337-345.